Comparative Pharmacology
Head-to-head clinical analysis: ACTONEL versus RISEDRONATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTONEL versus RISEDRONATE SODIUM.
ACTONEL vs RISEDRONATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and interfering with osteoclast activity.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, preventing osteoclast attachment and inducing osteoclast apoptosis.
35 mg orally once weekly or 5 mg orally once daily for osteoporosis; also 30 mg orally once weekly for Paget disease.
35 mg orally once weekly or 5 mg orally once daily, taken at least 30 minutes before the first food or beverage of the day with 6-8 ounces of plain water. For Paget disease: 30 mg orally once daily for 2 months.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (short for bisphosphonates due to rapid renal clearance); however, bone retention half-life is prolonged (>1 year) due to binding to hydroxyapatite.
Terminal elimination half-life: 480 hours (20 days) due to slow release from bone; clinical context: supports once-weekly dosing for osteoporosis.
Renal: 50-60% unchanged via glomerular filtration and active tubular secretion; Fecal: minor, biliary excretion negligible.
Renal excretion (unchanged, via glomerular filtration and active tubular secretion): 50-65% of absorbed dose. Fecal excretion: minor, <5% as unabsorbed drug. Biliary excretion: negligible.
Category C
Category D/X
Bisphosphonate
Bisphosphonate